oa Southern African Journal of Gynaecological Oncology - The art of prescribing trastuzumab for HER2-positive breast cancer : review
|Article Title||The art of prescribing trastuzumab for HER2-positive breast cancer : review|
|© Publisher:||Medpharm Publications|
|Journal||Southern African Journal of Gynaecological Oncology|
|Publication Date||Jan 2011|
|Pages||16 - 26|
|Keyword(s)||Dosing regimens, HER2-positive breast cancer, Patient eligibility, Resistance, Tolerability, Trastuzumab and University of Pretoria|
The human epidermal growth factor receptor 2 (HER2) is overexpressed in HER2-positive breast cancer. This confers characteristics associated with an overall poor prognosis, with early metastases to major visceral sites and a relative resistance to chemotherapy. Trastuzumab is a humanised monoclonal therapeutic antibody that specifically targets HER2 receptor overexpressing breast cancer cells, inhibiting their growth and proliferation, and inducing their regression. It is licensed for metastatic and early HER2-positive breast cancer, determined by slide-based testing techniques. Trastuzumab dosing regimens are aimed at increasing its efficacy, while minimising its potentially undesirable effects which include cardiotoxicity and the development of resistance.
Article metrics loading...